NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free VIR Stock Alerts $10.22 -0.17 (-1.64%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$10.13▼$10.5950-Day Range$7.63▼$11.9052-Week Range$7.61▼$27.48Volume1.24 million shsAverage Volume1.05 million shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$33.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vir Biotechnology alerts: Email Address Vir Biotechnology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside228.5% Upside$33.57 Price TargetShort InterestBearish5.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 22 Articles This WeekInsider TradingSelling Shares$1.53 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.04) to ($3.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.58 out of 5 starsMedical Sector432nd out of 908 stocksBiological Products, Except Diagnostic Industry67th out of 153 stocks 3.3 Analyst's Opinion Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageVir Biotechnology has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.79% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 3.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VIR. Previous Next 2.6 News and Social Media Coverage News SentimentVir Biotechnology has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Vir Biotechnology this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,525,844.00 in company stock.Percentage Held by Insiders15.60% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Vir Biotechnology are expected to grow in the coming year, from ($4.04) to ($3.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThis is the ONLY AI story you should be worried aboutA.I. is creeping into every aspect of our daily lives… According to billion-dollar fund manager, Louis Navellier, it’s never been more important to A.I.-proof your wealth. He lays out three simple steps to take ASAP in his latest video.Click here to watch it now. About Vir Biotechnology Stock (NASDAQ:VIR)Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.Read More VIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VIR Stock News HeadlinesMay 5, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) PT Raised to $12.00May 5, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Stock Rating Reaffirmed by Needham & Company LLCMay 6, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vir Biotechnology Amid Promising HDV and HBV Treatment MilestonesMay 4, 2024 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Rating of "Moderate Buy" by AnalystsMay 4, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Shares Gap Up on Better-Than-Expected EarningsMay 3, 2024 | markets.businessinsider.comHold Rating on Vir Biotechnology Amid Financial Concerns and Clinical Trial UncertaintyMay 3, 2024 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call TranscriptMay 6, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 3, 2024 | seekingalpha.comVir Biotechnology Provides Some Hope For Its Beleaguered ShareholdersMay 3, 2024 | finance.yahoo.comVir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | finance.yahoo.comQ1 2024 Vir Biotechnology Inc Earnings CallMay 2, 2024 | investorplace.comVIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024May 2, 2024 | msn.comVir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67MMay 2, 2024 | businesswire.comVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comVir Biotechnology earnings preview: what Wall Street is expectingApril 30, 2024 | finance.yahoo.comVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024April 28, 2024 | finance.yahoo.comWith 53% ownership, Vir Biotechnology, Inc. (NASDAQ:VIR) boasts of strong institutional backingApril 28, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Trading Up 7.6%April 27, 2024 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low at $7.65April 26, 2024 | msn.comSouthern policies help level up investment from East AsiaApril 18, 2024 | finance.yahoo.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsApril 18, 2024 | businesswire.comVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.April 16, 2024 | morningstar.comVir Biotechnology IncApril 11, 2024 | finance.yahoo.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 11, 2024 | businesswire.comVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024April 4, 2024 | finance.yahoo.comVir Biotechnology Inc CEO Backer De Sells 72,995 SharesSee More Headlines Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/06/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:VIR CUSIPN/A CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Target$33.57 High Stock Price Target$110.00 Low Stock Price Target$12.00 Potential Upside/Downside+228.5%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-615,060,000.00 Net Margins-677.69% Pretax Margin-690.97% Return on Equity-32.58% Return on Assets-26.97% Debt Debt-to-Equity RatioN/A Current Ratio12.90 Quick Ratio9.05 Sales & Book Value Annual Sales$39.49 million Price / Sales34.81 Cash FlowN/A Price / Cash FlowN/A Book Value$11.82 per share Price / Book0.86Miscellaneous Outstanding Shares134,500,000Free Float113,518,000Market Cap$1.37 billion OptionableOptionable Beta0.47 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Marianne De Backer M.B.A. (Age 55)M.Sc., Ph.D., CEO & Director Comp: $4.47MMr. Sung H. Lee (Age 54)Executive VP & CFO Comp: $968.45kDr. Ann M. Hanly Ph.D. (Age 54)Executive VP & Chief Technology Officer Comp: $896.07kDr. Jeff Calcagno M.D. (Age 63)Executive VP & Chief Business Officer Comp: $860.49kDr. Klaus Frueh Ph.D. (Age 64)Co-Founder & Scientific Advisor Comp: $177.66kDr. Lawrence Corey M.D. (Age 76)Co-Founder & Scientific Advisor Dr. Louis J. Picker M.D.Co-Founder & Scientific AdvisorDr. Jennifer Eileen Towne Ph.D.Executive VP & Chief Scientific OfficerMs. Heather Rowe ArmstrongVice President of Investor RelationsMs. Vanina De Verneuil J.D.Executive VP, General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVARelay TherapeuticsNASDAQ:RLAYCureVacNASDAQ:CVACBeam TherapeuticsNASDAQ:BEAMAvid BioservicesNASDAQ:CDMOView All CompetitorsInsiders & InstitutionsTexas Permanent School Fund CorpBought 1,012 shares on 5/6/2024Ownership: 0.056%Nordea Investment Management ABBought 87,190 shares on 5/2/2024Ownership: 0.175%Baillie Gifford & Co.Sold 18,484 shares on 5/1/2024Ownership: 2.935%Mirae Asset Global Investments Co. Ltd.Sold 163,377 shares on 5/1/2024Ownership: 0.037%China Universal Asset Management Co. Ltd.Bought 10,414 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VIR Stock Analysis - Frequently Asked Questions Should I buy or sell Vir Biotechnology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares. View VIR analyst ratings or view top-rated stocks. What is Vir Biotechnology's stock price target for 2024? 7 brokers have issued 1 year price targets for Vir Biotechnology's shares. Their VIR share price targets range from $12.00 to $110.00. On average, they expect the company's stock price to reach $33.57 in the next twelve months. This suggests a possible upside of 228.5% from the stock's current price. View analysts price targets for VIR or view top-rated stocks among Wall Street analysts. How have VIR shares performed in 2024? Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR shares have increased by 1.6% and is now trading at $10.22. View the best growth stocks for 2024 here. When is Vir Biotechnology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our VIR earnings forecast. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.51. The business had revenue of $56.38 million for the quarter, compared to analyst estimates of $11.71 million. Vir Biotechnology had a negative net margin of 677.69% and a negative trailing twelve-month return on equity of 32.58%. The firm's revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) EPS. What ETFs hold Vir Biotechnology's stock? ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM) and iShares Genomics Immunology and Healthcare ETF (IDNA).SPDR S&P 600 Small Cap ETF (SLY). What is George Scangos' approval rating as Vir Biotechnology's CEO? 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Vir Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (2.93%), Principal Financial Group Inc. (0.34%), Nordea Investment Management AB (0.18%), Texas Permanent School Fund Corp (0.06%), Mirae Asset Global Investments Co. Ltd. (0.04%) and Hennion & Walsh Asset Management Inc. (0.03%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VIR) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersCould Your Accounts Be Frozen?Allegiance GoldAI “wealth window” is closing June 25thParadigm PressThe asset beating inflation by 4xColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingMysterious Gold Leverage Just AnnouncedStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
